Multilingual ePROs with Short Time Windows: how to protect data quality in global trials

Multilingual ePROs with short time windows are among the most challenging aspects in global clinical trials. 

Patients must complete assessments in the right language, at the right time, within the protocol-defined window. When this does not happen, CROs may face missing data, late entries, protocol deviations, and reduced reliability of patient-reported outcomes. 

This is why multilingual ePRO is not just a translation feature. It is a data quality capability.

What a Short Time Window means in ePRO studies

A short time window is the specific period in which a patient must complete an ePRO assessment for the response to be considered valid or protocol-compliant.

This is common in studies involving:

• daily symptom diaries;
• post-dose tolerability assessments;
• pain or fatigue scales;
• nocturnal assessments;
• pre-visit questionnaires;
• flare-up or event-driven diaries.

The problem is simple: if a patient completes the assessment too late, the data may no longer reflect the intended clinical moment.

For example, a post-dose symptom scale completed six hours late may still contain useful information, but it may not be valid for the endpoint as originally designed. This can affect compliance rates, data interpretation and site follow-up activities.

The FDA PRO guidance explains the importance of reliable patient-reported outcome measures when they are used to support medical product claims. Similarly, research on the impact of missing ePRO data in clinical trials highlights how incomplete patient-reported outcome data can affect the quality of analyses, especially when PROs support primary or secondary endpoints.

If your study relies on time-sensitive patient-reported outcomes, discover how ACTide ePRO supports controlled ePRO data collection.

Why Multilingual ePRO is more than translation

In global trials, multilingual ePRO means more than displaying the same questionnaire in different languages.

Each patient-facing element must be clear, validated and consistent:

• questionnaire text;
• instructions;
• reminders;
• help messages;
• error messages;
• date and time formats;
• confirmation screens;
• local language variants.

This becomes even more important when validated scales are involved. Instruments such as PROMIS, EQ-5D, BPI or disease-specific questionnaires cannot be translated informally without risking loss of meaning.

The PROMIS translation methodology includes forward translation, back-translation, expert review, harmonisation and cognitive debriefing. The EQ-5D translation process follows a standardised protocol to ensure equivalence with the English source version.

CROs must also consider regional language variants. European Spanish and Latin American Spanish may not always be interchangeable. The ISPOR recommendations on PRO translation and linguistic validation underscore the importance of carefully managing language versions in multinational trials.

If the wording is unclear, patients may delay, misunderstand or abandon the assessment. In short-window ePRO studies, even a small language issue can become a data quality risk.

For multilingual studies, ACTide ePRO helps CROs manage patient-reported outcome workflows within an integrated eClinical environment.

What Regulatory Guidance Implies for ePRO Time Window Compliance

Regulatory guidance does not usually define one universal ePRO time window. Instead, it focuses on data reliability, traceability, system control and endpoint validity.

The FDA guidance on electronic systems in clinical investigations provides recommendations on electronic records, electronic systems and electronic signatures used in regulated clinical research.

The EMA guideline on computerised systems and electronic data in clinical trials covers electronic data acquisition tools, validation, user management, security and data lifecycle requirements.

The ICH E6(R3) Good Clinical Practice guideline reinforces a risk-based approach to trial conduct and to the reliability of clinical data. The EU recommendations on decentralised clinical trials also stress the need to safeguard participant rights, data reliability and endpoint validity when digital tools are used.

For CROs, this means that ePRO time windows, reminders, audit trails and language versions should be designed as part of the quality strategy before study launch.

If your ePRO study requires strong control over timing, language and data traceability, request an ACTide demo to see how these workflows can be configured.

How technology reduces the risk of missed or Out-of-Window ePRO data

The right ePRO software can reduce operational risk by guiding patients, monitoring compliance, and providing study teams with real-time visibility.

For multilingual ePROs with short time windows, CROs should look for:

• automated reminders based on the opening and closing of each window;
• time-zone management for global studies;
• multilingual push notifications, SMS or email reminders;
• offline mode for patients with limited connectivity;
• real-time dashboards by site, country, language and patient;
• automatic tracking of missed or late entries;
• audit trail of patient interactions.

This is where ePRO software becomes operationally critical. A reminder must reach the patient at the right time, in the right language and through the right channel.

For study teams, dashboards should make compliance issues visible early. If one site, country or language group shows lower completion rates, CROs can intervene before the issue affects data quality at scale.

When connected with ACTide eCRF and supported by ACTide Data Manager Tools & Services, ePRO data can flow into a more controlled clinical data management process, reducing manual reconciliation and fragmented review.

To move from reactive data cleaning to proactive ePRO oversight, explore ACTide Data Manager Tools & Services.

What to Look for in an ePRO Vendor for Multilingual Trials

Not every ePRO vendor is ready for multilingual studies with strict timing rules.

Before choosing an ePRO system, CROs should ask five practical questions:

1. Can the platform manage validated scale versions in multiple languages?
   This includes version control, language assignment and controlled updates.
2. Can time windows be configured by assessment, visit, event, country and patient time zone?
   Short-window logic should not depend on manual workarounds.
3. Can reminders be adapted by language, timing, frequency and channel?
   Patients should receive the right message at the right moment.
4. Can the study team monitor compliance in real time?
   Dashboards should show missed windows, late entries and completion trends.
5. Can ePRO data integrate with the EDC?
   Integration reduces manual reconciliation and supports cleaner clinical data workflows.

With ACTide Designer, CROs can configure complex study workflows. With ACTide eCRF and ACTide ePRO, patient-reported data and site-entered data can be managed within the same eClinical ecosystem.

Multilingual ePRO with tight time windows is not just a feature. It is a capability that protects data quality, patient compliance and operational control in global trials.

Is your ePRO vendor ready for multilingual studies with complex time windows?